key: cord-0956145-lykmjvtv
authors: Nasir, Nosheen; Rehman, Fazal; Omair, Syed Furrukh
title: Risk factors for bacterial infections in patients with moderate to severe COVID‐19: A case‐control study
date: 2021-04-15
journal: J Med Virol
DOI: 10.1002/jmv.27000
sha: b25cb170639269c286dedfaa4627877eea316453
doc_id: 956145
cord_uid: lykmjvtv

Adverse outcomes in coronavirus infection disease‐19 (COVID‐19) patients are not always due to the direct effects of the viral infection, but often due to bacterial coinfection. However, the risk factors for such bacterial coinfection are hitherto unknown. A case‐control study was conducted to determine risk factors for bacterial infection in moderate to critical COVID‐19. Out of a total of 50 cases and 50 controls, the proportion of cases with severe/critical disease at presentation was 80% in cases compared to 30% in controls (p < 0.001). The predominant site was hospital‐acquired pneumonia (72%) and the majority were Gram‐negative organisms (82%). The overall mortality was 30%, with comparatively higher mortality among cases (42% vs. 18%; p = 0.009). There was no difference between procalcitonin levels in both groups (p = 0.883). In multivariable logistic regression analysis, significant independent association was found with severe/critical COVID‐19 at presentation (AOR: 4.42 times; 95% CI: 1.63–11.9) and use of steroids (AOR: 4.60; 95% CI: 1.24–17.05). Notably, 64% of controls were administered antibiotics despite the absence of bacterial coinfection or secondary infection. Risk factors for bacterial infections in moderate to critically ill patients with COVID‐19 include critical illness at presentation and use of steroids. There is widespread empiric antibiotic utilization in those without bacterial infection.

Coronavirus infection disease-19 (COVID-19) pandemic has claimed more than 1 000 000 lives to date and its long-term impact is yet to be determined. Respiratory viral infections have been well known to predispose patients to coinfections and these lead to increased disease severity and mortality as was observed in the 1918 influenza outbreak, where most mortalities were due to simultaneous bacterial infection. 1 Bacterial coinfection also led to poor outcomes in the 2009 H1N1 influenza pandemic. 2 The incidence of bacterial coinfection in COVID-19 ranges from 3% to 30%. 3, 4 Zhou et al. 5 showed that in the current COVID-19 pandemic, 50% of patients who died, had secondary bacterial infections, while another study showed the presence of both bacterial and fungal infection. 6 Due to similar clinical phenotype and difficulties in identifying COVID-19 disease from atypical bacterial pneumonia or nosocomial pneumonia some guidelines advise empirical antibiotics. 7 In a study conducted at 38 hospitals in Michigan 56.6% patients received empirical antibiotics therapy. 8 Abbreviations: COVID-19, coronavirus infection disease-19; C-RP, C-reactive protein; ERC, Ethics Review Committee; IQR, interquartile range; MDR, multi-drug resistant; MRSA, methicillinresistant Staphylococcus aureus.

Studies indicate that bacterial coinfection and secondary infection complicate COVID-19 though regional data is scarce. 6 Moreover, risk factors for these infections need to be better elucidated.

Antimicrobials are used empirically which may lead to antimicrobial resistance in the long term. Hence, it is imperative to conduct comparative studies to identify those COVID-19 patients who are candidates for empirical antibiotic therapy and curtail the widespread injudicious use of antibiotics. The objective of this study is was to determine the risk factors of bacterial infections in COVID-19

patients. Secondary objectives were to determine differences in the organisms and sensitivity patterns in moderate versus severe/critical COVID-19 and risk factors for mortality.

A case-control study was conducted from February 2020 to June 2020 at a tertiary care center in Karachi, Pakistan. Cases were defined as patients who had polymerase chain reaction confirmed, graded as moderate to severe/critical COVID-19 as per World Health Organization (WHO) criteria for severity, 9 and had evidence of bacterial infection based on isolation of bacteria in any of the culture specimens collected during admission along with symptoms and signs consistent with infection. Controls were defined as patients who had graded as moderate to severe/critical COVID-19 as per WHO criteria for severity 9 but who did not develop a bacterial infection during admission.

All adult patients (age ≥ 18 years) hospitalized with moderate and severe/critical COVID-19 as per WHO definition for severity 10 

A total of 50 cases and 50 controls were included in the analysis after making relevant exclusions over a period of 4 months from February 2020 to June 2020. The median age of cases was 58 years (IQR) and of controls was 62 years (IQR). The overall male to female ratio was 2.8 and gender distribution was similar between the groups. The most frequent comorbid were diabetes and hypertension in both groups. The severity of illness was significantly different in both the groups with a high proportion (80%) of severe/critical COVID-19 patients among cases compared to 30% in controls (p < 0.001).

In the univariable analysis, the median C-reactive protein (C-RP) and median neutrophil to lymphocyte ratio (NLR) were significantly higher in cases compared to controls (Table 1) in males compared to females. 12, 13 We had very few communityacquired infections and the majority were hospital-acquired. This is similar to a study conducted by Hughes et al. 14 from the UK where only 3.2% coinfections were reported and a study from Spain describing the incidence of coinfections. 15 This was also confirmed in a meta-analysis where the reported prevalence of coinfections was 3.5%. 16 Majority of the patients in our cohort developed hospitalacquired infections. This is consistent with other reported literature. 16, 17 The most common site of infection was pneumonia and this is in concordance with initial reports from China. 17 Gram-negative infections have dominated as far as the type of organisms is concerned and this is similarly seen in studies reported from other parts of the world describing super-infections or secondary bacterial infections. 15, 17 There is a lack of reported literature on the sensitivity patterns of organisms isolated. In our study, we found MDR Acinetobacter as the predominant pathogen causing hospital-acquired infections and MRSA as the main cause of coinfection in COVID-19 in our patients. A case series of 19 patients from Iran has described Acinetobacter baumanii in the majority of patients requiring ICU admission 18 which reflects epidemiological similarity to Pakistan. In our study, the overall mortality was 30% and was higher in those who had bacterial infections. This is also consistent with data reported from Europe and parts of Asia. 16, 19 Moreover, we found that overall antibiotic utilization was 82% and was 64% in patients who had no evidence of bacterial infection. This has also been similarly reported 19 indicating widespread injudicious use of antibiotics which can potentiate the problem of antimicrobial resistance. In our study, we did not find procalcitonin to be a reliable marker of distinguishing patients who had bacterial infections and those who did not have bacterial infections. Although studies have described procalcitonin levels to remain normal in severe COVID-19, whether they increase in bacterial infections has not been reported and indicates the need of large comparative studies exploring this relationship. 20 Our study is the first comparative study with regard to bacterial infections in the setting of moderate and severe to critical COVID-19 and describes the sensitivity pattern of organisms in addition to clearly classifying them into the community and hospital-acquired infections.

Our study is limited as it's a single-center experience which might affect generalizability. Moreover, we did not have molecular methods and genotyping available for our bacterial isolates and information on the isolation rate of the prevalent Gram-negative and MRSA in non-COVID-19 patients over the study period was not available to draw comparisons with rates of infection seen in COVID-19 patients.

Our study highlights the need for improving antibiotic stewardship practices and reserving antibiotics for those who are severely ill with COVID-19 at presentation and require treatment with systemic steroids and provides insight into the lack of utility of serum procalcitonin as a marker of bacterial sepsis in this setting.

The 1918 influenza pandemic and its legacy

Critical illness from 2009 pandemic influenza A (H1N1) virus and bacterial co-infection in the United States

COVID-19, superinfections and antimicrobial development: what can we expect?

Community acquired co-infection in COVID-19: a retrospective observational experience

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing

Co-infections in people with COVID-19: a systematic review and meta-analysis

Empiric antibacterial therapy and community-onset bacterial co-infection in patients hospitalized with COVID-19: a multi-hospital cohort study

Clinical management of COVID-19

Clinical management of COVID-19: interim guidance. Clinical management of COVID-19: interim guidance

CDC/NHSN Surveillance Definitions for Specific Types of Infections

Sex-and age-specific differences in COVID-19 testing, cases, and outcomes: a populationwide study in Ontario

Sex differences in case fatality rate of COVID-19: insights from a multinational registry

Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting

Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study

Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis

Nosocomial infection among patients with COVID-19: a retrospective data analysis of 918 cases from a single center

Evaluation of bacterial coinfections of the respiratory tract in COVID-19 patients admitted to ICU

Bacterial infections and patterns of antibiotic use in patients with COVID-19

Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis

Risk factors for bacterial infections in patients with moderate to severe COVID-19: a case-control study

The authors declare that there are no conflict of interests.

The study was submitted for ethical approval to the Aga Khan University Ethics Review Committee and received exemption (ERC reference number: 2020-5178-14123). Consent to participate was not required because there was no direct interaction with participants. The study was eligible for exemption as data was collected from records and no personal identifiers were recorded or used.

Nosheen Nasir conceived the idea, major contributor to the manuscript, collected and analyzed data. Fazal Rehman conceived idea, contributed to manuscript, and collected the data. Syed Furrukh Omair collected data and contributed to the manuscript. All authors read and approved the manuscript.

http://orcid.org/0000-0003-1610-8748